

**Amendments to the Drawings:**

The attached sheet of drawings includes changes to Figure 1. Please replace original Figure 1 with Replacement Figure 1, filed herewith. Figure 1 has been amended to include a “G” at nucleotide position 80 of the sequence set forth in the figure. A marked-up copy of Figure 1, with annotations, is included herewith.

**REMARKS**

Entry of the forgoing amendment is respectfully requested under 37 C.F.R. §1.312. Claims 1, 2, 4, and 6-9 (re-numbered as 1-7) have been allowed, as stated in the Notice of Allowance mailed September 30, 2005. The issue fee is due December 30, 2005, and has not been paid.

Figure 1 shows the nucleotide sequence of the 5' promoter region of human FcRIIB gene (SEQ ID NO:1) (*see* page 6, lines 24-25 of the specification). This nucleotide sequence is also set forth as GenBank Accession No. X52888, which is expressly incorporated by reference in the instant application (*see, e.g.,* page 6, lines 5-9, page 17, lines 3-5, and page 37, lines 15-16). Applicant has noted that the sequence set forth in Figure 1, as filed, is missing a guanidine nucleotide residue ("G") at nucleotide position 80. This residue is included in GenBank Accession No. X52888 and is included in SEQ ID NO:1 of the Sequence Listing filed in the instant application on May 23, 2002. Accordingly, Applicants submit herewith a substitute Figure 1 that includes a "G" at position 80 as set forth in GenBank Accession No. X52888. A marked-up copy of Figure 1, is included herewith. A copy of GenBank Accession No. X52888 is also included herewith as Exhibit 1.

Applicant respectfully submits that, because GenBank Accession No. X52888 was published prior to the filing date of the instant application and was expressly incorporated by reference in the instant application, this amendment does not add new matter. Further, Applicant respectfully submits that this amendment does not involve any substantial additional work by the Patent and Trademark Office. Accordingly, it is respectfully requested that the Examiner allow the amendment to Figure 1.

**CONCLUSION**

Therefore, in view of the above amendments and remarks, it is respectfully requested that entry of the amendment be allowed. The Examiner is respectfully requested to contact the undersigned at the telephone number indicated below if the Examiner has any question regarding this amendment.

Dated: November 1, 2005

Respectfully submitted,

By 

Lisa D. Tyner

Registration No.: 51,619

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700


(212) 753-6237 (Fax)

Attorneys/Agents For Applicant



## FIGURE 1

GCCATCCTGA CATACCTCCT TGTCCTTGTT CCACAACCTCA GCAGTGAGTC TGGGTTATGA  
CAATAGAGAA AATTAAATGG ATGGTAGGTG GCCTGGAGTC CCCATGCTCA ATTTCAAGAA  
GCATCCAGAT TCCAGGGCCT GGGTCTCCAA ATGGAAGTAG AAGTACTAGA AGATTGCTGG  
TGCACGCTGT CCT<sup>\*</sup>GCATCAC CCTTTCTCAG GAGGATAGAG ACTGAAACAG GAGGTTCTGA  
GCTGAGTTTT GGTGACCATT TCCCTCTTTC TCCAGAGGC CCAGGCCAGC TGTGGCCTCA  
GAGGAAGAAG AAGGGAGTTG TTTCCCTAGT TTCTAAAATT TCTGTGAATT TGAACATGGG  
CTACACCAGA TTTATTCTGG GAAGCTCTGA ATCTTCTAGG AGGGAAAGAC TGAGAGGAAA  
GAGGGTGGAA AGGGAGGAGC CTGTGATAAA ACAGAACATT<sup>\*</sup> TCTTTTTCAC TTCCCCTTTC  
AGACTCCAGA ATTTGTTTGC CCTCTAGGGT AGAATCGCCA AGCTTTGAG A GAAGGCTGTG<sup>A</sup>  
ACTGCTGTGC TCTGGGCGCC ACGTCGCTCC AGGGAGTGAT GGAATCCTG TCATTCTTAC  
CTGTCCTTGC CACTGAGAGT GACTGGGCTG ACTGCAAGTC CCCCCAGCCT TGGGGTCATA  
TGCTTCTGTG GACAGCTGTG CTATTCCTGG GTGAGT



[Register]

Search   for

## Details

Range: from  to  ☐ Reverse complemented strand Features: ☐ SNP ☐ CDD ☒

## Links

```
/number=1
```

1	gccatcctga	catacctcct	tgtccttggt	ccacaactca	gcagtgagtc	tgggttatga
61	caatagagaa	aattaaatgg	atggtaggtg	gcctggagtc	cccattgctca	atttcaagaa
121	gcatccagat	tccagggcct	gggtctccaa	atggaagtag	aagtactaga	agattgctgg
181	tgcacgctgt	cctgcatcac	cctttctcag	gaggatagag	actgaaacag	gaggttctga
241	gctgagtttt	ggtgaccatt	tccctctttc	tcccagaggc	ccaggccagc	tgtggcctca
301	gaggaagaag	aagggagttg	tttccctagt	ttctaaaatt	tctgtgaatt	tgaacatggg
361	ctacaccaga	tttattctgg	gaagctctga	atcttctagg	agggaaagac	tgagaggaaa
421	gaggggtggaa	agggaggagc	ctgtgataaa	acagaacatt	tctttttcac	ttcccccttc
481	agactccaga	atttgtttgc	cctctagggt	agaatcgcca	agctttgaga	gaaggctgtg
541	actgctgtgc	tctgggcgc	acgtcgctcc	agggagtgat	gggaatcctg	tcattcttac
601	ctgtccttgc	cactgagagt	gactgggctg	actgcaagtc	ccccagcct	tggggtcata
661	tgttctgtg	gacagctgtg	ctattcctgg	gtgagt		

//

NCBI | NLM | NIH